Editas Medicine Crescita futura
Future criteri di controllo 2/6
Editas Medicine is forecast to grow earnings and revenue by 2.8% and 36.5% per annum respectively. EPS is expected to grow by 13.9% per annum. Return on equity is forecast to be -184.7% in 3 years.
Informazioni chiave
2.8%
Tasso di crescita degli utili
13.9%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 27.1% |
| Tasso di crescita dei ricavi | 36.5% |
| Rendimento futuro del capitale proprio | -184.7% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 23 Oct 2024 |
Aggiornamenti recenti sulla crescita futura
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12Recent updates
Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Sep 26Editas Medicine: A Risk/Reward Worth Considering
Sep 25Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet
Aug 23Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
Feb 25Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 43 | -271 | -311 | -257 | 14 |
| 12/31/2025 | 18 | -262 | -269 | -235 | 16 |
| 12/31/2024 | 23 | -249 | -182 | -176 | 17 |
| 6/30/2024 | 67 | -193 | -172 | -165 | N/A |
| 3/31/2024 | 69 | -166 | -151 | -146 | N/A |
| 12/31/2023 | 78 | -153 | -137 | -132 | N/A |
| 9/30/2023 | 25 | -195 | -156 | -152 | N/A |
| 6/30/2023 | 19 | -206 | -169 | -165 | N/A |
| 3/31/2023 | 23 | -219 | -168 | -164 | N/A |
| 12/31/2022 | 20 | -220 | -181 | -177 | N/A |
| 9/30/2022 | 26 | -201 | -176 | -170 | N/A |
| 6/30/2022 | 32 | -184 | -171 | -162 | N/A |
| 3/31/2022 | 26 | -186 | -174 | -164 | N/A |
| 12/31/2021 | 26 | -193 | -172 | -164 | N/A |
| 9/30/2021 | 24 | -214 | -176 | -169 | N/A |
| 6/30/2021 | 81 | -167 | -189 | -183 | N/A |
| 3/31/2021 | 92 | -135 | -180 | -175 | N/A |
| 12/31/2020 | 91 | -116 | -187 | -180 | N/A |
| 9/30/2020 | 92 | -91 | -106 | -99 | N/A |
| 6/30/2020 | 33 | -132 | -79 | -71 | N/A |
| 3/31/2020 | 24 | -142 | -73 | -66 | N/A |
| 12/31/2019 | 21 | -134 | -47 | -41 | N/A |
| 9/30/2019 | 14 | -121 | -86 | -80 | N/A |
| 6/30/2019 | 25 | -103 | -66 | -61 | N/A |
| 3/31/2019 | 30 | -108 | -57 | -52 | N/A |
| 12/31/2018 | 32 | -110 | -50 | -46 | N/A |
| 9/30/2018 | 29 | -121 | -76 | -72 | N/A |
| 6/30/2018 | 21 | -132 | -96 | -92 | N/A |
| 3/31/2018 | 17 | -120 | N/A | -102 | N/A |
| 12/31/2017 | 14 | -120 | N/A | -9 | N/A |
| 9/30/2017 | 11 | -124 | N/A | 2 | N/A |
| 6/30/2017 | 6 | -118 | N/A | 13 | N/A |
| 3/31/2017 | 6 | -111 | N/A | 29 | N/A |
| 12/31/2016 | 6 | -97 | N/A | -50 | N/A |
| 9/30/2016 | 6 | -71 | N/A | -45 | N/A |
| 6/30/2016 | 6 | -57 | N/A | -39 | N/A |
| 3/31/2016 | 2 | -86 | N/A | -9 | N/A |
| 12/31/2015 | 2 | -73 | N/A | -5 | N/A |
| 9/30/2015 | 1 | -66 | N/A | -1 | N/A |
| 6/30/2015 | 0 | -62 | N/A | 9 | N/A |
| 3/31/2015 | N/A | -17 | N/A | -13 | N/A |
| 12/31/2014 | N/A | -14 | N/A | -9 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: EDIT is forecast to remain unprofitable over the next 3 years.
Guadagni vs Mercato: EDIT is forecast to remain unprofitable over the next 3 years.
Guadagni ad alta crescita: EDIT is forecast to remain unprofitable over the next 3 years.
Ricavi vs Mercato: EDIT's revenue (36.5% per year) is forecast to grow faster than the US market (8.9% per year).
Ricavi ad alta crescita: EDIT's revenue (36.5% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: EDIT is forecast to be unprofitable in 3 years.